Preclinical Assessment of HIV Vaccines and Microbicides by Repeated Low-Dose Virus Challenges
Open Access
- 19 July 2005
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 2 (8) , e249
- https://doi.org/10.1371/journal.pmed.0020249
Abstract
Trials in macaque models play an essential role in the evaluation of biomedical interventions that aim to prevent HIV infection, such as vaccines, microbicides, and systemic chemoprophylaxis. These trials are usually conducted with very high virus challenge doses that result in infection with certainty. However, these high challenge doses do not realistically reflect the low probability of HIV transmission in humans, and thus may rule out preventive interventions that could protect against “real life” exposures. The belief that experiments involving realistically low challenge doses require large numbers of animals has so far prevented the development of alternatives to using high challenge doses. Using statistical power analysis, we investigate how many animals would be needed to conduct preclinical trials using low virus challenge doses. We show that experimental designs in which animals are repeatedly challenged with low doses do not require unfeasibly large numbers of animals to assess vaccine or microbicide success. Preclinical trials using repeated low-dose challenges represent a promising alternative approach to identify potential preventive interventions.Keywords
This publication has 44 references indexed in Scilit:
- Retroviral Recombination In Vivo: Viral Replication Patterns and Genetic Structure of Simian Immunodeficiency Virus (SIV) Populations in Rhesus Macaques after Simultaneous or Sequential Intravaginal Inoculation with SIVmac239Δ vpx/ Δ vpr and SIVmac239Δ nefJournal of Virology, 2005
- Multiple Vaginal Exposures to Low Doses of R5 Simian‐Human Immunodeficiency Virus: Strategy to Study HIV Preclinical Interventions in Nonhuman PrimatesThe Journal of Infectious Diseases, 2005
- A Period of Transient Viremia and Occult Infection Precedes Persistent Viremia and Antiviral Immune Responses during Multiple Low-Dose Intravaginal Simian Immunodeficiency Virus InoculationsJournal of Virology, 2004
- Repeated Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge Results in the Same Viral and Immunological Kinetics as High-Dose Challenge: a Model for the Evaluation of Vaccine Efficacy in Nonhuman PrimatesJournal of Virology, 2004
- What Constitutes Efficacy for a Human Immunodeficiency Virus Vaccine that Ameliorates Viremia: Issues Involving Surrogate End Points in Phase 3 TrialsThe Journal of Infectious Diseases, 2003
- Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunityNature, 2002
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- An Animal Model for Antilentiviral Therapy: Effect of Zidovudine on Viral Load during Acute Infection after Exposure of Macaques to Simian Immunodeficiency VirusAIDS Research and Human Retroviruses, 1994
- The transmission dynamics of human immunodeficiency virus (HIV)Philosophical Transactions of the Royal Society of London. B, Biological Sciences, 1988
- Nonparametric estimators of the mean tolerance in bioassayBiometrika, 1973